Rybelsus vs Ozempic

Both labels describe semaglutide the same way: a GLP-1 analogue with 94 percent sequence homology to human GLP-1, acting as a receptor agonist that selectively binds to and activates the GLP-1 receptor. The sentence is the same in both documents, because the molecule is the same.

What differs is everything around the molecule: how it is taken, how often, how the dose is counted, and which warnings the form of administration makes possible.

The oral label, application NDA213051, covers Rybelsus tablets at 3 mg, 7 mg and 14 mg and Ozempic tablets at 1.5 mg, 4 mg and 9 mg. The injection is a separate application, NDA209637, supplied as pens delivering doses of 0.25 mg, 0.5 mg, 1 mg and 2 mg, and also as single-dose prefilled syringes of 0.25 mg, 0.5 mg or 1 mg.

So the name Ozempic on its own no longer identifies a form. The numbers are not comparable across the two either: 14 mg by mouth and 2 mg by injection are the top maintenance doses of their own documents, not two ways of describing one amount.

The oral label sets out conditions the injection has no equivalent for: take the tablet once daily on an empty stomach in the morning with water, up to 4 ounces and no other liquid, swallow it whole without splitting, crushing, chewing or dissolving it, and wait at least 30 minutes before eating, drinking anything else or taking other oral medicines.

The injection label says to administer it once weekly at any time of day, with or without meals, subcutaneously in the abdomen, thigh or upper arm, and that a missed dose can be given within 5 days. For anyone weighing the two forms, this is the practical difference the documents actually describe.

Both are indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes, and both carry a cardiovascular indication alongside it. The population in that one is not worded the same: the injection label covers adults with type 2 diabetes and established cardiovascular disease, the oral label covers adults with type 2 diabetes who are at high risk for those events.

The injection label carries a third indication that the tablets do not: reducing the risk of sustained decline in kidney function, end-stage kidney disease and cardiovascular death in adults who have type 2 diabetes together with chronic kidney disease. Its dosing section adds a matching instruction, to increase to 1 mg once weekly after at least four weeks at 0.5 mg for that purpose.

Neither label lists weight loss as an approved use. Semaglutide does hold a weight management approval in the United States, under the name Wegovy, which is a third document with its own indication.

Both carry the boxed warning about the risk of thyroid C-cell tumours, and both are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2.

Below the box the lists diverge in ways that follow directly from the form. The oral label warns about severe gastrointestinal adverse reactions and states that the tablets are not recommended in patients with severe gastroparesis. The injection label warns never to share a pen between patients, even if the needle is changed, which is an instruction a tablet cannot need.

The reported common adverse reactions are close but not identical, both at the 5 percent threshold: nausea, vomiting, diarrhoea, abdominal pain and constipation in both, with decreased appetite additionally listed for the tablets.